P+P advised Robert Bosch Venture Capital on the financing of GNA Biosolutions
P+P advised the Robert Bosch Venture Capital GmbH with regard to a series B financing round for GNA Biosolutions GmbH. The existing shareholders include Mey Capital Matrix, KfW and the company founder.
Headquartered in Martinsried, Bavaria, GNA Biosolutions GmbH develops instruments and assays for the ultra-rapid detection of pathogens, based on its proprietary laser PCR technology.
GNA Biosolutions was founded in 2010 as a spin-off from the Institute of Photonics and Optoelectronics at the Ludwig Maximilian University in Munich.
Robert Bosch Venture Capital GmbH (RBVC) is the Bosch Group's own venture capital company, a leading global technology and services provider. RBVC invests worldwide in innovative start-up companies in all stages of development.
P+P Pöllath + Partners advised Robert Bosch Venture Capital GmbH on corporate and financing matters with the following interdisciplinary team:
- Dr. Michael Inhester (lead, partner, corporate, Munich)
- Eva-Juliane Stark (associate, corporate, Berlin)
